Omeprazole (Omeprazole) Patent Expiration, LOE Window & CMS Spending
Omeprazole (Omeprazole) by Dexcel Technologies: FDA Orange Book LOE 2030-01-31, 15 AB generics, $463.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Dexcel Technologies |
| FDA Application & Pathway | N022032 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-01-31 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 15 |
| 2024 CMS Total Public Spend | $463.1M |
| 2024 Medicare Part D Spend | $366.7M |
| 2024 Medicaid Spend | $96.4M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 773.6% 2-yr change) |